In a study, a meta-analysis was conducted to evaluate the efficacy of the anti-Claudin-18.2-targeted therapy, zolbetuximab, in comparison to other anti-programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors for treating gastric/gastroesophageal junction (G/GEJ) carcinoma [22]. This evidence concerns the gene PDCD1 and carcinoma.